$NBIS

Ryan Charles E sold $13.3M of NBIS

Ryan Charles E sold 50,000 shares of Nebius Group N.V. (NBIS) at an average of $265.53 ($263.32–$269.64, $13.28M total) across 6 trades on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ryan Charles E
Published Aug 18, 2026, 9:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NBIS
Neutral
medium confidence
Mentioned
$NBIS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NBISNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price range ($263.32 to $269.64), and that it was executed across multiple trades under a pre-arranged 10b5-1 plan.

02

Market read

This is primarily a positioning/sentiment datapoint rather than a fundamental update, since it is an insider sale under a pre-arranged plan with no new company guidance or events.

03

What to watch

The filing does not state whether other insiders or the company have concurrent buybacks, lockups, or new guidance; without those, the sale alone is a weak catalyst.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-14

Background

The article is a SEC Form 4 insider transaction disclosure for Nebius Group N.V., director Ryan Charles E.

Company-level read

Ticker impact

$NBISNeutralMedium confidence
Context

Nebius Group N.V. disclosed director Ryan Charles E selling about 50,000 shares in open-market trades for roughly $13.28M under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect is more sentiment/flow related than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and the article provides no accompanying company-specific operational or financial catalyst.

Market effects

No sector-level implications disclosed; this is an issuer-specific insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations, so traders may overreact if they treat it as a signal.

Key entities

  • Nebius Group N.V.

    Company whose director insider sale was disclosed on Form 4.

  • Ryan Charles E

    Director who sold shares in open-market transactions under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NBISMed

Nebius stock breaks below $200 as CoreWeave’s debt scare spreads

Nebius Group (NBIS) fell 10.1% to $186.01 on October 14, 2026, breaking its $200 support level. The decline was driven by fears of excessive debt in the AI sector, sparked by CoreWeave (CRWV) bonds yielding near 15%. Nebius's funding costs may rise due to this market sentiment. The company's stock trades at 38x trailing sales and 7x forward sales, with analysts' price targets ranging from $84 to $410.

$NBISMed

Why is Nebius stock sliding today?

Nebius Group NV (NBIS) stock fell 4.1% to $178.4 in pre-open trading, extending losses due to rising borrowing costs, higher bond yields for peer CoreWeave, and Gartner's warning about AI infrastructure spending risks. Insider selling and a bearish stance from short-seller Michael Burry also contributed. The broader tech sector selloff, driven by higher Treasury yields, added pressure.

$NBISMed

Nebius Group (NBIS) Shares Drop 10% Amid Tech Sell-Off; P/S Rati

Nebius Group (NBIS) shares fell 10.08% to $186.01 on October 14, 2026, amid a broader tech sector sell-off. The company's P/S ratio is 38.39, significantly above its historical median and industry norms. Nebius has a GF Score of 52, with strong momentum but weak valuation and financial strength. Insiders have sold $318.2 million in shares over the past year, while some institutional investors have increased their stakes.